Novartis execs on compliance: “Why be afraid of the truth?”
Novartis’s Shannon Thyme Klinger and Klaus Moosmayer talk to GIR about how the pharmaceutical company changed its approach to compliance in the midst of a series of government investigations.
To read more
Subscribe to Global Investigations Review
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the Global Investigations Review experts.